Capricor Therapeutics released new data from its HOPE-3 open-label extension study for Deramiocel, showing a reduced rate of decline in upper limb function for Duchenne muscular dystrophy patients. This positive data comes ahead of a critical FDA decision on November 22, following a prior advisory panel's negative vote on the drug's effectiveness.
Capricor Therapeutics has disclosed new, seemingly positive data from its HOPE-3 open-label extension study for Deramiocel, a treatment for Duchenne muscular dystrophy. This is a significant development as the company faces an FDA decision on November 22, especially after an advisory panel previously voted against the drug's effectiveness due to concerns about data analysis. The new data highlights a substantial reduction in the rate of disease progression and outperformance against natural history, which could sway the FDA's final decision. For traders, this presents a high-stakes situation: a positive FDA decision could send CAPR soaring, while a negative one could lead to a sharp decline, making the stock highly volatile in the short term. The long-term implications depend entirely on the FDA's upcoming ruling.